Table 1.
Participant Group | Gender | Age (yr) | Education Level (yr) | Ethnicity | Age at Onset of HL (yr) | CI Type | Age at Implant (yr) | Length of CI Use |
---|---|---|---|---|---|---|---|---|
Normal hearing | F = 11; M = 1 | 54.75 | 17.00 | Caucasian | — | — | — | — |
Unilateral CI | F = 6; M = 4 | 58.60 | 15.80 | Caucasian | 18.68 | N = 6; AB = 4 | 46.22 | 17.00 |
Bilateral CI | F = 10; M = 2 | 65.67 | 15.27 | Caucasian | 23.32 | N = 4; AB = 8; ME = 1 | 56.75 | 8.92 |
Short-electrode CI | F = 4; M = 8 | 53.92 | 16.00 | Caucasian | 21.75 | S8 = 1; S12 = 5; L24 = 6 | 49.67 | 4.75 |
Total | F = 31; M = 15 | 58.24 | 16.08 | Caucasian | 21.25 | N = 22; AB = 12; ME = 1 | 50.88 | 10.22 |
Notes: AB = Advanced Bionics Corporation (Valencia, CA); F = female; HL = hearing loss; L24 = Nucleus Hybrid L24 (22 intracochlear electrodes on 17-mm array); M = male; ME = Med-El Corporation (Durham, NC); N = Nucleus; S8 = Nucleus Hybrid S8 (6 intracochlear electrodes on 10-mm array); S12 = Nucleus Hybrid S12 (10 intracochlear electrodes on 10-mm array).